Showing 3841-3850 of 7113 results for "".
- Sirnaomics Accelerates Clinical Development of STP705 for isSCC, BCChttps://practicaldermatology.com/news/sirnaomics-accelerates-clinical-development-of-stp705-for-isscc-bcc/2461535/Sirnaomics Ltd. is advancing the clinical development of STP705 for the treatment of squamous cell carcinoma in situ (isSCC) and basal cell carcinoma (BCC). Based on positive clinical readouts from a Phase IIb study for isSCC and a Phase II study for BCC, Sirnaomics is formul
- Game On: Top Derm Video Game Boosts Clinical Decision Making Among Seasoned Doctorshttps://practicaldermatology.com/news/game-on-top-derm-video-game-boosts-clinical-decision-making-among-seasoned-doctors/2461534/Medical video games increase the competence and clinical decision-making of practicing physicians, a new study by Level Ex shows. Substantial research has demonstrated video-game-based medical training’s effectiveness in the short-term. These studies primarily focused on medi
- Laura Geller Beauty's Signature Foundation Scores the National Psoriasis Foundation's Seal of Recognitionhttps://practicaldermatology.com/news/laura-geller-beautys-signature-foundation-scores-the-national-psoriasis-foundations-seal-of-recognition/2461533/The National Psoriasis Foundation granted its Seal of Recognition to Laura Geller Beauty's Signature Baked Balance-n-Brighten Color Correcting Foundation. This is the first makeup product to receive the National Psoriasis Foundation Seal of Recognition.
- Bristol Myers Squibb Receives Positive CHMP Opinion for Once-Daily Sotyktu as Plaque Psoriasis Treatmenthttps://practicaldermatology.com/news/bristol-myers-squibb-receives-positive-chmp-opinion-for-once-daily-sotyktu-as-plaque-psoriasis-treatment/2461522/Four months after receiving FDA approval, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of Sotyktu (deucravacitinib; Bristol Myers Squibb) for the treatment of adults with moderate-to-severe plaque psoriasis. 
- Revealed: The Genetic Basis of 13 Pigment Traits and Their Relationship with Diseaseshttps://practicaldermatology.com/news/revealed-the-genetic-basis-of-13-pigment-traits-and-their-relationship-with-diseases/2461515/Researchers have uncovered the genetic basis of 13 pigment traits and their association with diseases. Using the GCAT cohort, researchers built a comprehensive analysis strategy leading to the identification of phototype associated-diseases in a total of nearly 20,000 Ca
- Dong-A ST: Phase 3 Trial Shows Therapeutic Equivalence Between Plaque Psoriasis Drug Candidate DMB-3115 and Stelarahttps://practicaldermatology.com/news/dong-a-st-demonstrates-therapeutic-equivalence-between-plaque-psoriasis-drug-candidate-dmb-3115-and-stelara-in-phase-3-trial/2461504/South Korea-based Dong-A ST announced that therapeutic equivalence and safety were established between DMB-3115 and Stelara (ustekinumab; Janssen Biotech), the reference drug, in global phase 3 trials. Stelara is indicated for plaque psoriasis, psoriatic arthritis,
- Beekman 1802 Pledges to Put Nurses First in 2023https://practicaldermatology.com/news/beekman-1802-pledges-to-put-nurses-first-in-2023/2461487/Beekman 1802 is launching "
- Endo Removes Qwo from Market Due to Concerns About Injection Site Bruising, Skin Discolorationhttps://practicaldermatology.com/news/endo-removes-qwo-from-market-due-to-concerns-about-injection-site-bruising-skin-discoloration/2461467/Endo International plc is ceasing the production and sale of Endo Aesthetics' Qwo (collagenase clostridium histolyticum-aaes) in light of market concerns about the extent and variability of bruising following initial treatment as well as the potential for prolonged skin discoloratio
- UCB's Bimekizumab Performs Well in Hidradenitis Suppurativahttps://practicaldermatology.com/news/ucbs-bimekizumab-performs-well-in-hidradenitis-suppurativa/2461464/UCB’s bimekizumab may be a promising treatment approach in adults with moderate to severe hidradenitis suppurativa, according to topline results from two Phase 3 studies, BE HEARD I and BE HEARD II. The positive results from these two studies will form the basis of global reg
- Hydrafacial, DOCTOR BABOR Collab for New Collagen HA Boosterhttps://practicaldermatology.com/news/hydrafacial-doctor-babor-collab-for-new-collagen-ha-booster/2461461/The Beauty Health Company’s Hydrafacial launched a new booster co-created with BABOR Skincare. The new DOCTOR BABOR Collagen HA booster is inspired by DOCTOR BABOR’s formulations and developed with the BABOR Laboratories in Germany. “Hydrafacial has cre